Pumitamig plus elfetabart drozuntecan shows encouraging early activity in small cell lung cancer
The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according ...
Sep 12, 2026
0
15









